HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Friday, 20 September 2019

August’s CEAs.....

We’ve completed our quick search for CEA’s published last month.   In the right-hand column of this blog is a CEA Archive of all records.  Below are those in our areas of interest.

  • Canning P, Tawfick W, Whelan N, Hynes N, Sultan S. Cost-effectiveness analysis of endovascular versus open repair of abdominal aortic aneurysm in a high-volume center. J Vasc Surg. 2019;70(2):485-96.
  • Long MW, Polacsek M, Bruno P, Giles CM, Ward ZJ, Cradock AL, et al. Cost-Effectiveness Analysis and Stakeholder Evaluation of 2 Obesity Prevention Policies in Maine, US. J Nutr Educ Behav. 2019.
  • Men P, Qu S, Luo W, Li C, Zhai S. Comparison of lixisenatide in combination with basal insulin versus other insulin regimens for the treatment of patients with type 2 diabetes mellitus inadequately controlled by basal insulin: systematic review, network meta-analysis and cost-effectiveness analysis. Diabetes Obes Metab. 2019.
  • Pereira C, Areia M, Dinis-Ribeiro M. Cost-utility analysis of genetic polymorphism universal screening in colorectal cancer prevention by detection of high-risk individuals. Dig Liver Dis. 2019.
  • Townsend T, Blostein F, Doan T, Madson-Olson S, Galecki P, Hutton DW. Cost-effectiveness analysis of alternative naloxone distribution strategies: First responder and lay distribution in the United States. Int J Drug Policy. 2019.
  • Zhou K, Jiang C, Li Q. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. Lung Cancer. 2019;136:98-101.
  • Zimmermann M, Frey K, Hagedorn B, Oteri AJ, Yahya A, Hamisu M, et al. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis. Vaccine. 2019;37(41):6039-47.

Posted by at